Search Results

Functionalizing novel PHIP variants in ancestry specific Acute Myeloid Leukemia

AML risk stratification established by previous studies do not reflect survival outcomes observed in Black patients. Exome sequencing of 100 Black AML patients revealed the novel variants previously not affiliated with AML, including PHIP. Using multiomic patient sample captures and GEMMs, we will functionalize variants in PHIP and assess if they drive leukemogenesis and/or therapy resistance. The overall goal of this work is to implement inclusive genetic assessment tools for AML diagnosis.

FDA Approves Immunotherapy for Earlier Use in B-cell Acute Lymphoblastic Leukemia

The Leukemia & Lymphoma Society Welcomes Five Members to its Board of Directors

Let's Talk About Childhood Cancer: The Impact of Leukemia in Black Children

Decitabine

Decitabine is FDA approved to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia.

Pegaspargase

Pegaspargase is FDA approved in combination with other chemotherapy medications to treat people who have acute lymphoblastic leukemia (ALL).

Obecabtagene autoleucel

Obecabtagene autoleucel is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Honoring My Daughter’s Legacy By Continuing Her Fight

Rasburicase

Rasburicase is FDA approved for the initial management of plasma uric acid levels in patients with leukemia, lymphoma and solid tumors who are receiving certain types of anticancer therapy expected to result in elevated plasma uric acid.

Calaspargase pegol-mknl

Calaspargase pegol-mknl is FDA approved as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. 

 

Myeloma Awareness Month: Aiming for more

Nelarabine

Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.

Pentostatin

Pentostatin is FDA approved as a single-agent treatment for both untreated and alfa-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia (abnormally low white blood count), thrombocytopenia (reduced platelet count), or disease-related symptoms.

Revumenib

Revumenib is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.

SAVE THE DATE AGAIN: GETTING MARRIED AFTER CANCER

My name’s Dustin. December 3, 2016 was the date that I was supposed to get married to KT. It was a Saturday. We had that date set for over a year, but there was no wedding—we canceled it the Tuesday before. KT informed most of our guests with an explanatory text: “So, I have some unfortunate news. We’re going to have to call off the wedding this weekend. Dust got cold feet…and leukemia.”

Busulfan

Busulfan is FDA approved in combination with cyclophosphamide as a conditioning regimen prior to allogeneic stem cell transplantation for people who have chronic myeloid leukemia.

Idelalisib

Idelalisib is FDA approved to treat patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

Mercaptopurine

Mercaptopurine is FDA approved to treat people who have acute lymphoblastic leukemia as part of a combination regimen.

Asparaginase

Asparaginase is FDA approved in combination with chemotherapy to treat people who have acute lymphoblastic leukemia.

Quizartinib

Quizartinib is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test. 

Glasdegib

Glasdegib ​is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Limitation of Use: Glasdegib has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.

 

Asparaginase erwinia chrysanthemi (recombinant)- rywn

Rylaze® is a component of a multi-agent chemotherapeutic regimen indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase. 

Asciminib

Asciminib is indicated for the treatment of adult patients with: 

• Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). 
  This indication is approved under accelerated approval based on major molecular response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
• Previously treated Ph+ CML in CP.
• Ph+ CML in CP with the T315I mutation. 

A phase 1 study of CB-012, a CRISPR-edited allogeneic CAR-T targeting CLL1, in patients with acute myeloid leukemia

In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia." Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.